Validation of Syndromic Surveillance for Respiratory Pathogen Activity by van den Wijngaard, Cees et al.
Syndromic surveillance is increasingly used to signal 
unusual illness events. To validate data-source selection, 
we retrospectively investigated the extent to which 6 respi-
ratory syndromes (based on different medical registries) 
reﬂ   ected respiratory pathogen activity. These syndromes 
showed higher levels in winter, which corresponded with 
higher laboratory counts of Streptococcus pneumoniae, 
respiratory syncytial virus, and inﬂ  uenza virus. Multiple lin-
ear regression models indicated that most syndrome varia-
tions (up to 86%) can be explained by counts of respiratory 
pathogens. Absenteeism and pharmacy syndromes might 
reﬂ  ect nonrespiratory conditions as well. We also observed 
systematic syndrome elevations in the fall, which were un-
explained by pathogen counts but likely reﬂ  ected rhinovirus 
activity. Earliest syndrome elevations were observed in ab-
senteeism data, followed by hospital data (+1 week), phar-
macy/general practitioner consultations (+2 weeks), and 
deaths/laboratory submissions (test requests) (+3 weeks). 
We conclude that these syndromes can be used for respira-
tory syndromic surveillance, since they reﬂ  ect patterns in 
respiratory pathogen activity.
E
arly warning surveillance for emerging infectious dis-
ease has become a priority in public health policy since 
the anthrax attacks in 2001, the epidemic of severe acute 
respiratory syndrome in 2003, and the renewed attention 
on possible inﬂ  uenza pandemics. As a result, new surveil-
lance systems for earlier detection of emerging infectious 
diseases have been implemented. These systems, often la-
beled “syndromic surveillance,” beneﬁ  t from the increasing 
timeliness, scope, and diversity of health-related registries 
(1–6). Such alternative surveillance uses symptoms or clini-
cal diagnoses such as “shortness of breath” or “pneumonia” 
as early indicators for infectious disease. This approach not 
only allows clinical syndromes to be monitored before lab-
oratory diagnoses, but also allows disease to be detected for 
which no additional diagnostics were requested or avail-
able (including activity of emerging pathogens). Our study 
assessed the suitability of different types of healthcare data 
for syndromic surveillance of respiratory disease.
We assumed that syndrome data—to be suitable for 
early detection of an emerging respiratory disease—should 
reﬂ  ect patterns in common respiratory infectious diseases 
(7–10). Therefore, we investigated the extent to which 
time-series of respiratory pathogens (counts per week in 
existing laboratory registries) were reﬂ  ected in respiratory 
syndrome time-series as recorded in 6 medical registries in 
the Netherlands. We also investigated syndrome variations 
that could not be explained by pathogen counts. As an indi-
cation for syndrome timeliness, we investigated the delays 
between the syndrome and pathogen time-series. 
Methods
Syndrome Data Collection and Case Deﬁ  nitions
We deﬁ  ned syndrome data as data in health-related 
registries that reﬂ   ect infectious disease activity without 
identifying causative pathogen(s) or focusing on pathogen-
speciﬁ  c symptoms (such as routine surveillance data for 
inﬂ  uenza-like illness [11] or surveillance of acute ﬂ  accid 
paralysis for polio [12]).
Registries for syndrome data were included if they 
met the following criteria: 1) registration on a daily basis;
2) availability of postal code, age, and sex; 3) availability 
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of retrospective data (>2 years); and 4) (potential) real-time 
data availability.
Six registries were selected (Table 1) that collected data 
on work absenteeism, general practice (GP) consultations, 
prescription medications dispensed by pharmacies, diag-
nostic test requests (laboratory submissions) (13), hospital 
diagnoses, and deaths. In all registries, data were available 
for all or a substantial part of 1999–2004. For the GP, hos-
pital, and mortality registry, deﬁ  nition of a general respira-
tory syndrome was guided by the case deﬁ  nitions and codes 
found in the International Classiﬁ  cation of Diseases, 9th 
revision, Clinical Modiﬁ  cation (ICD-9-CM), as selected by 
the Centers for Disease Control and Prevention (Atlanta, 
GA, USA) (www.bt.cdc.gov/surveillance/syndromedef). 
For the laboratory submissions and the pharmacy syn-
drome, we selected all data that experts considered indica-
tive of respiratory infectious disease (for detailed syndrome 
deﬁ  nitions, see online Technical Appendix, available from 
www.cdc.gov/EID/content/14/6/917-Techapp.pdf). 
Respiratory Pathogen Counts 
As a reference for the syndrome data, we included 
speciﬁ  c pathogen counts for 1999–2004 from the follow-
ing sources: 1) Weekly Sentinel Surveillance System of the 
Dutch Working Group on Clinical Virology (which cov-
ers 38%–73% of the population of the Netherlands [14] for 
routine laboratory surveillance of respiratory syncytial vi-
rus [RSV], inﬂ  uenza A virus, inﬂ  uenza B virus, rhinovirus, 
Mycoplasma pneumoniae, parainﬂ  uenza virus, enterovirus, 
and adenovirus); 2) 6 regional public health laboratories for 
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Table 1. Registries from which syndrome data were obtained, the Netherlands, 1999–2004* 
Data type Period
%
Coverage†
Respiratory syndrome 
definitions‡ Analyzed data
International
code system Registry
Absenteeism 2002–2003 80§ Reported sick 
employees; no further 
medical information
Sick leave reports of 
employees
– Statistics 
Netherlands (CBS),
www.cbs.nl
General 
practice
consultations
2001–2004 1–2 Symptoms and 
diagnoses indicating 
respiratory infectious 
disease
Symptoms and 
diagnoses recorded in 
practice or telephone 
consultations and in 
home visits 
ICPC Netherlands
Information Network 
of General Practice 
(LINH), 
www.nivel.nl/linh
Pharmacy 
dispensations
2001–2003 85 Prescribed medications 
indicative for respiratory 
infectious disease
Prescription
medications dispensed 
in Dutch pharmacies, 
coded according to the 
WHO ATC 
classification
ATC Foundation for 
Pharmaceutical
Statistics,
http://www.sfk.nl
Hospitalization 1999–2004 99 General respiratory 
symptoms/diagnoses; 
specific respiratory 
biologic agent diagnoses 
Discharge and 
secondary diagnoses, 
date of hospitalization
ICD-9-CM Dutch  National 
Medical Register 
(LMR)
Laboratory 
submissions¶
2001–2004
(1999–2000 
excluded due 
to unstable 
coverage)
16 All submissions for 
microbiologic diagnostic 
tests on respiratory 
materials; all 
submissions for serologic 
testing on known specific 
respiratory pathogens; all 
submissions for 
Legionella or 
Streptococcus
pneumoniae antigen 
tests on urine 
Laboratory submission 
requests for diagnostic 
testing
– National Infectious 
Diseases
Information System 
(ISIS) (13)
Mortality 1999–2004 100 General respiratory 
symptoms/diagnoses; 
specific respiratory 
biologic agent diagnoses
Date of death, primary 
cause of death, 
complicating factors, 
other additional causes 
of death
ICD-10 CBS
*ICPC, International Classification of Primary Care; WHO, World Health Organization; ATC, Anatomic Therapeutic Chemical Classification System; ICD-
9-CM, International Classification of Diseases, 9th revision, Clinical Modification; ICD-10, International Classification of Diseases, 10th revision.  
†Percentage of total population, 16.3 million. 
‡For detailed syndrome definitions and codes, see online Technical Appendix, available from www.cdc.gov/EID/content/14/6/917-Techapp.pdf. 
§Percentage of working population, 8 million. 
¶Diagnostic test requests with both negative and positive results. Syndromic Surveillance for Respiratory Pathogens 
respiratory disease–related counts of Streptococcus pneu-
moniae (data in 2003–2004 were interpolated for 2 labora-
tories during short periods of missing data; total coverage 
24%); and 3) national mandatory notiﬁ  cations of pertus-
sis. The networks for respiratory pathogen counts are other 
networks than the earlier described laboratory submissions 
network for syndrome data. 
Data Analysis and Descriptive Statistics
Data were aggregated by week and analyzed by using 
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). For 
the GP, pharmacy, and laboratory submissions registries, 
we expressed the respiratory counts as a percentage of to-
tal weekly counts to adjust for the inﬂ  uence of holidays 
and, for laboratory submissions, changes in the number of 
included laboratories over time. By looking at the graphs, 
we explored the relationship between the time-series of re-
spiratory pathogens and syndromes and calculated Pearson 
correlation coefﬁ  cients.
Linear Regression Models
To investigate whether the respiratory syndromes 
reﬂ  ect patterns in respiratory pathogen counts, we con-
structed multiple linear regression models. These models 
estimated respiratory syndrome levels at a certain time 
with, as explanatory variables, the lagged (range of –5 to 
+5 weeks) pathogen counts as explanatory variables. We 
used linear regression of the untransformed syndrome to 
estimate the additive contributions of individual pathogens 
to the total estimated syndrome. We assumed a constant 
syndrome level attributable to factors other than the respi-
ratory pathogens and constant scaling factors for each of 
the lagged pathogens. A forward stepwise regression ap-
proach was used, each step selecting the lagged pathogen 
that contributed most to Akaike’s information criterion of 
model ﬁ  t (15). Each pathogen entered the model only once 
and only if it contributed signiﬁ  cantly (p<0.05). Negative 
associations (e.g., between enteroviruses, which peak in 
summer, vs. respiratory syndromes, which peak in winter) 
were excluded to avoid noncausal effects.
To discriminate between primary and secondary in-
fections by S. pneumoniae (as a complication of respira-
tory virus infection) (16–19), we used the residuals from 
regressing S. pneumoniae counts on other pathogens as the 
variable for S. pneumoniae (instead of its counts) for all the 
earlier described models for respiratory syndromes.
We checked for autocorrelation in the residuals of the 
models with hierarchical time-series models (using SPLUS 
6.2) (20,21). We calculated R2 values to estimate to what 
extent respiratory pathogen counts explain variations in 
syndromes. To explore to what extent seasonal variation 
could be a confounder, we also calculated R2 values of the 
models after adding seasonal variables (sine and cosine 
terms) and R2 values for seasonal terms alone. We also in-
vestigated the pathogen-speciﬁ  c effects in the models, by 
calculating the standardized parameter estimates before 
and after adding seasonal terms.
The models were used to estimate the expected syn-
drome level with 95% upper conﬁ  dence limits (UCLs). We 
considered distinct syndrome elevations that exceeded the 
UCLs, as unexplained by the models (for model details, see 
online Technical Appendix).
Timeliness
We investigated the timeliness of the registry syn-
dromes in 2 ways: 1) as a measure of differences in timeli-
ness between registries, we evaluated the time delays of the 
syndromes relative to each other by calculating for each of 
the syndromes the time lag that maximized Pearson corre-
lation coefﬁ  cient with the hospital registry (as a reference); 
2) by estimating the time delays between each of the syn-
dromes and the lagged pathogens included in its regression 
model.
Results
Data Exploration and Descriptive Statistics
Respiratory syndrome time series were plotted for all 
registries (Figure 1). The Christmas and New Year holi-
days coincided with peaks and dips in the pharmacy and 
absenteeism syndromes (not shown). Because these results 
were probably artifacts, we smoothed these yearly peaks 
and dips and censored them in the analyses performed on 
the absenteeism registry, in which they had a strong inﬂ  u-
ence on outcomes. For all registries, the respiratory syn-
dromes demonstrated higher levels of activity in winter, 
which overlapped or coincided roughly with the seasonal 
peaks of inﬂ  uenza A, inﬂ  uenza B, RSV, and (albeit less 
pronounced) S. pneumoniae laboratory counts (Figure 1). 
Infections with parainﬂ  uenza virus, M. pneumoniae, ad-
enovirus, and rhinovirus were detected slightly more fre-
quently during winter (data not shown). Bordetella pertus-
sis and enterovirus showed seasonal peaks only in summer 
(data not shown).
The seasonal peaks in laboratory counts of inﬂ  uenza 
A, inﬂ  uenza B, and RSV corresponded with peaks in the 
GP, pharmacy, and hospital syndromes. Other syndromes 
did have less obvious correspondence. Each year, around 
October, the respiratory syndrome showed a peak in the 
GP (2001–2004), pharmacy (2001–2003), and absentee-
ism (2002–2003) registries (Figure 1, panels A–C) that was 
observed neither for the other registries nor in any of the 
laboratory pathogens.
We calculated Pearson correlation coefﬁ  cients between 
the different unlagged time series of respiratory pathogens 
and syndromes (Table 2). Syndrome time series in all reg-
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istries correlated strongly with S. pneumoniae (unadjusted 
total counts). The hospital, GP, pharmacy, and laboratory 
submissions data strongly correlated with RSV and inﬂ  u-
enza A counts (Table 2). Mortality data correlated strongly 
with inﬂ  uenza A (r = 0.65) and inﬂ  uenza B (r = 0.50) infec-
tions. The highest correlations between pathogen time se-
ries were between S. pneumoniae and the other pathogens 
(up to 0.51 with inﬂ  uenza A, Table 3).
Linear Regression Models
Table 4 presents, for each registry, the time lag (in 
weeks) that maximized the model ﬁ  t of regressing syndrome 
on pathogens. For the GP, hospital, mortality, and pharma-
cy data, the respiratory pathogens explained the syndrome 
variation very well (78%–86%). Variations in the absentee-
ism syndrome could be explained for 68% by variations in 
the pathogen counts. Although the laboratory submissions 
syndrome had the lowest explained variance, still 61% of 
the variations in this syndrome were explained by variations 
in pathogen counts. Hierarchical time-series models did not 
show signiﬁ  cant autocorrelation in the residuals of the mod-
els with pathogen counts as explanatory variables (20,21).
When seasonal terms were added to the model, the 
variations in the mortality syndrome were just as well ex-
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Figure 1. Respiratory syndrome time series and laboratory pathogen counts in the Netherlands. Respiratory syndromes were deﬁ  ned 
for the 6 registries deﬁ  ned in Table 1: A) absenteeism, B) general practice (GP) consultations, C) pharmacy, D) laboratory submissions, 
E) hospitalizations, and F) mortality counts. Pathogens plotted were respiratory syncytial virus (RSV), inﬂ  uenza A, inﬂ  uenza B, and 
Streptococcus pneumoniae [1999–2004 or part of this period, panels A–C]. Recurrent unexplained syndrome elevations in October are 
circled. Pathogen counts are daily counts of pathogens found in laboratory survellience.Syndromic Surveillance for Respiratory Pathogens 
plained as by the model with only pathogen counts (Table 
5; R2 remains 78%), while by the model with only seasonal 
terms, the explained variance was much lower (only 52%, 
Table 5). For the hospitalizations, laboratory submissions, 
and GP data, only slightly more syndrome variation was 
explained by adding seasonal terms. With only seasonal 
terms, the explained variance for these syndromes was 
clearly lower than with only pathogens in the models 
(8%–11% lower, Table 5). However, for the absenteeism 
and, to a lesser extent, the pharmacy data, the model with 
both pathogen and seasonal terms clearly explained more 
syndrome variations (Table 5, absenteeism 68% vs. 80%; 
pharmacy 80% vs. 87%). Furthermore, for the absenteeism 
data, the model with only seasonal terms had an even high-
er R2 than the model with only pathogens, whereas for the 
pharmacy data, the R2 with only seasonal terms was only 
slightly lower (3%, Table 5).
Table 6 shows that for mortality, hospitalizations, 
laboratory submissions, and GP data, the pathogens with 
the highest effect clearly were RSV, inﬂ  uenza A, and in-
ﬂ  uenza B, with no or only modest decline in standardized 
parameter estimates after adding seasonal terms. For the 
GP and hospital data, some pathogens became insigniﬁ  -
cant after seasonal terms were added (GP: rhinovirus and 
adenovirus; hospital: parainﬂ  uenza virus). For the phar-
macy data, half of all pathogen variables became insig-
niﬁ  cant after seasonal terms were added, whereas for the 
absenteeism data, almost all pathogens became insigniﬁ  -
cant (Table 6).
Several syndrome observations exceeded the 95% 
UCLs of the models (0–10/registry/year), which indi-
cates that those syndrome observations deviated strongly 
from model predictions. The recurrent elevation in Octo-
ber of the absenteeism, GP, and pharmacy syndrome sev-
eral times exceeded the UCLs (October 2001: pharmacy 
and GP; 2002: absenteeism; 2003: GP, absenteeism; not 
shown), which indicated that the model could not explain 
these elevations.
Timeliness
In Figure 2, for each registry, the difference in timeli-
ness with the hospital registry is indicated by the lag that 
maximizes R2. The absenteeism syndrome (green line) pre-
ceded the hospital syndrome by 1 week, followed by the 
GP-based and prescription-based syndromes at +1 week 
and the syndrome based on mortality and laboratory sub-
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Table 2. Pearson correlation coefficients between time series of syndromes and laboratory pathogen counts, the Netherlands, 1999–
2004*†
Pathogen Hospital GP Mortality Pharmacy
Laboratory 
submissions Absenteeism
RSV 0.74 0.67 0.41 0.58 0.53 0.47
Influenza A 0.57 0.61 0.65 0.60 0.47 0.35
Influenza B 0.31 0.39 0.50 0.42 0.34 0.33
Streptococcus pneumoniae 0.73 0.71 0.56 0.75 0.58 0.69
Rhinovirus 0.33 0.34 0.33 0.33 NS 0.35
Parainfluenza 0.20 NS NS NS 0.25 NS
Adenovirus 0.37 0.35 0.33 0.36 NS 0.34
Enterovirus 0.65 0.66 0.59 0.61 0.57 0.51
Mycoplasma pneumoniae 0.13 0.27 0.25 0.39 0.32 0.26
Bordetella pertussis NS NS NS NS NS NS
*GP, general practice; RSV, respiratory syncytial virus; NS, nonsignificant. Correlations >0.50 in boldface; p>0.05. 
†Unlagged.
Table 3. Pearson correlation coefficients between time series in respiratory pathogen counts, the Netherlands, 1999–2004*† 
Pathogen
S.
pneumoniae RSV
Influenza
A
Influenza
B RV PIV Adenovirus Enterovirus
Mycoplasma 
pneumoniae
Bordetella
pertussis
S. pneumoniae 1.00 0.35 0.51 0.36 NS 0.32 0.32 –0.44 0.21 0.31
RSV 1.00 0.23 NS 0.30 0.13 0.21 –0.30 0.19 NS
Influenza A 1.00 0.36 NS 0.12 0.24 –0.39 0.16 0.25
Influenza B 1.00 NS NS NS –0.30 0.25 0.21
RV 1.00 NS 0.21 NS NS NS
PIV 1.00 NS –0.19 NS NS
Adenovirus 1.00 –0.21 NS 0.14
Enterovirus 1.00 0.15 0.21
M. pneumoniae 1.00 NS
B. pertussis 1.00
*S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; NS, nonsignificant. Correlations 
>0.50 in boldface; p value >0.05. 
†Unlagged.RESEARCH
mission data at +2 weeks after the hospital syndrome (pro-
jected on x-axis, Figure 2).
The differences in timeliness between the syndromes 
and the pathogen surveillance data were reﬂ  ected by the 
regression models relating the syndromes to the (positive 
or negative) lagged pathogens (Table 4). Inﬂ  uenza A and 
inﬂ  uenza B had lags of 0–5 weeks, which suggests that 
the registry-syndromes were 0–5 weeks ahead of labora-
tory counts for these infections. Fluctuations in the time se-
ries of respiratory hospitalizations and the laboratory RSV 
counts seemed to appear in the same week (lag = 0). All 
other syndromes appeared to be 1–3 weeks later than the 
RSV counts, except absenteeism, which is 2 weeks earlier. 
Again, absenteeism seemed to be the earliest syndrome 
(2–5 weeks earlier than RSV, inﬂ  uenza A, and inﬂ  uenza 
B), followed by the hospital syndrome (0–2 weeks earlier), 
the GP-based and prescription-based syndromes (2 weeks 
earlier until 1 week later), the laboratory submission syn-
drome (1 week earlier until 2 weeks later), and the mortal-
ity syndrome (0–3 weeks later than RSV, inﬂ  uenza A, and 
inﬂ  uenza B).
Discussion 
We explored the potential of 6 Dutch medical reg-
istries for respiratory syndromic surveillance. Although 
several other studies also evaluated routine (medical) data 
for syndromic surveillance purposes (22–27), most evalu-
ated only 1 syndrome and correlated this only to inﬂ  uenza 
data. An exception is Bourgeois et al. (24), who validated 
a respiratory syndrome in relation to diagnoses of several 
respiratory pathogens in a pediatric population, and Cooper 
et al. (27), who estimated the contribution of speciﬁ  c re-
spiratory pathogens to variations in respiratory syndromes. 
Both studies concluded that RSV and inﬂ  uenza explain 
most of the variations in these syndromes, consistent with 
our ﬁ  ndings.
Our study shows that all syndrome data described in 
this study showed higher levels in winter, which corre-
sponded to the seasonal patterns of RSV, S. pneumoniae, 
and inﬂ  uenza A and B viruses. Linear regression showed 
that the syndromes can be explained by lagged laboratory 
counts for respiratory pathogens (up to 86%, highest ef-
fect of inﬂ  uenza A, inﬂ  uenza B, and RSV), which indi-
cates their potential usefulness for syndromic surveillance. 
Timeliness differed, with up to 5 weeks potential gain in 
early warning by syndromic data, compared with routine 
laboratory surveillance data.
A limitation of our study is the short duration of our 
time series, especially for absenteeism and pharmacy data. 
Therefore, whether our observed associations between syn-
dromes and pathogen counts can be generalized remains 
unclear.
We relied on laboratory pathogen counts as a proxy 
for their prevalence and the illness they cause. Changes in 
test volume over time would result in misclassiﬁ  cation bias 
(as noncausative pathogens will be detected as well). How-
ever, such changes are presumably dwarfed by changes 
during “truly” epidemic elevations of common respiratory 
pathogens. Additionally, laboratory diagnostics are mostly 
performed on hospitalized patients, and thus results inad-
equately reﬂ  ect activity of pathogens that predominantly 
cause mild illness.
By adding seasonal terms, we observed that for the 
absenteeism and, to a lesser extent, the pharmacy registry, 
the associations between the respiratory syndromes and the 
pathogen counts might be biased to some extent. For the 
GP, hospital, laboratory submission, and mortality data, 
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Table 4. All respiratory pathogen counts included as explanatory variables in the regression models, the Netherlands, 1999–2004*†
Syndrome data  RSV
Influenza
A
Influenza
B
S. pneumoniae
(residual) RV PIV Adenovirus Enterovirus
Mycoplasma 
pneumoniae
Bordetella
pertussis
Absenteeism 2 5 4 2 4 5 – – –
GP –1 1 2 –1 1 2 2 –– 3
Pharmacy –1 0 2 0 2 5 2 –5 3
Hospitalization 0 2 1 – –2 3 – – –
Laboratory 
submissions
–2 0 1 –3 – 2 – 5
Mortality 3 10 –– – – – –
*S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; GP, general practice; –, pathogen 
not included in model. 
†The lag time (in weeks) is indicated, that showed optimal fit between syndrome time-series and lagged pathogen counts included in the linear regression 
model; e.g., according to the model, the trend in hospitalizations precedes the influenza A laboratory counts by 2 weeks. 
Table 5. Syndrome variation that can be explained by either the 
pathogen counts, seasonal terms, or pathogen counts and 
seasonal terms together* 
Syndrome data 
Pathogens,
%
Pathogens and 
seasonal terms, % 
Seasonal
terms, % 
Absenteeism 68 80 79
GP 86 89 75
Pharmacy 80 87 77
Hospitalization 84 88 75
Laboratory 
submissions
61 63 53
Mortality 78 78 52
*Estimated by 3 different R
2 values for each registry: 1) for the syndromes 
explained by pathogen counts alone; 2) after adding seasonal terms to the 
pathogen model; and 3) for the syndromes explained by seasonal terms 
alone (sine and cosine parameters). GP, general practice. Syndromic Surveillance for Respiratory Pathogens 
season is probably not an important confounder for the as-
sociation between the syndromes and pathogens, because 
including seasonal terms in the models resulted in the same 
or only slightly higher explained syndrome variance (mea-
sured by R2). Models with seasonal terms alone mostly had 
lower explained variance than the pathogen models. For the 
GP and hospital data, some pathogens became insigniﬁ  cant 
after seasonal terms were added (Table 6) but not those 
pathogens with the largest effect estimates (RSV, inﬂ  uenza 
A and B). Therefore, we are conﬁ  dent in concluding that 
the GP, hospital, laboratory submission, and mortality syn-
dromes do reﬂ  ect pathogen activity sufﬁ  ciently for use in 
syndromic surveillance.
The higher R2 value of the absenteeism model with 
seasonal terms alone suggests seasonality of absenteeism 
caused by several nonrespiratory conditions (28,29). To 
some extent, this also applies to the pharmacy syndrome, 
which includes medications that are not speciﬁ  c for respi-
ratory infections (e.g., antimicrobial drugs). This could be 
validated in future studies by linking medications to illness. 
However, for both the absenteeism and pharmacy syn-
dromes, the variation explained by seasonal terms is prob-
ably overestimated to some extent because data for only 
2 and 3 years were used. Consequently, these time series 
contained less information on variation between different 
years than for the other registries, which beneﬁ  ts ﬁ  tting of 
a model with several sine and cosine terms.
To our knowledge, laboratory submission data (test 
requests) have not been evaluated before as a data source 
for syndromic surveillance. The modest explained variance 
for the laboratory submissions syndrome could possibly 
reﬂ  ect the limited use in our country of laboratory testing 
algorithms, which leads to substantial differences in diag-
nostic regimes for patients with similar clinical symptoms. 
In addition, occasional extra alertness by clinicians can 
make these data unreliable for surveillance. For instance, 
an unusual peak was observed in the laboratory submis-
sions syndrome in 1999, after the ofﬁ  cial announcement of 
an outbreak of Legionnaires’ disease (30).
An unexpected increase was also observed in the ab-
senteeism, GP, and pharmacy syndromes, which occurred 
consistently each year around October (2001–2004). These 
peaks preceded the syndrome peaks concurring with peaks 
in inﬂ  uenza A, inﬂ  uenza B, and RSV counts and may be 
caused by rhinovirus activity—and asthma exacerbations 
caused by rhinovirus—which usually rises in the fall (31–
33). Rhinovirus might go undetected because GP physi-
cians rarely ask for diagnostics if they suspect a nonbacte-
rial cause for relatively mild respiratory disease. Although 
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Figure 2. The (maximum) R2 by the lagged syndromes with the 
hospital syndrome as a reference. Aggregated by week, univariate 
Pearson correlation coefﬁ   cients were calculated of the hospital 
syndrome and each of the other syndromes. Note that the Pearson 
correlation coefﬁ  cients are calculated over different periods for the 
different registries because not all registries cover the same period 
(Table 1). Measured by the syndrome lag with the maximized R2, 
the timeliness differed between the registries in the following order: 
absenteeism, hospital, pharmacy/general practice (GP), mortality/
laboratory submissions (as projected on the x-axis). 
Table 6. Standardized parameter estimates (ȕs) for all respiratory pathogen counts included as explanatory variables in the regression 
models, before and after adding seasonal terms to the models*†  
Syndrome data  RSV
Influenza
A
Influenza
B
S.
pneumoniae
(residual) RV PIV Adenovirus Enterovirus
Mycoplasma 
pneumoniae
Bordetella
pertussis
Absenteeism 0.31/
(NS)
0.27/
(NS)
0.33/
(NS)
0.28/
0.12
0.19/
(NS)
0.20/
(NS)
–_ _ _
GP 0.60/
0.51
0.32/
0.32
0.20/
0.16
0.13/
0.10
0.07/
(NS)
0.14/
0.08
0.07/
(NS)
_ 0.06/
0.05
_
Pharmacy 0.51/
0.54
0.27/
0.22
0.24/
(NS)
0.25/
0.11
0.16/
0.08
0.16/
(NS)
0.08/
(NS)
_ 0.12/
(NS)
0.11/
0.11
Hospitalization 0.60/
0.44
0.36/
0.34
0.21/
0.12
_ 0.13/
0.05
0.09/
(NS)
__ _ _
Laboratory 
submissions
0.49/
0.47
0.19/
0.20
0.22/
0.18
0.28/
0.22
_ 0.17/
0.08
_ _ 0.10/
0.10
_
Mortality 0.40/
0.36
0.52/
0.51
0.24/
0.24
__ _ _ _ _ _
*S. pneumoniae, Streptococcus pneumoniae; RSV, respiratory syncytial virus; RV, rhinovirus; PIV, parainfluenza virus; GP, general practice; –, pathogen 
not included in model; NS, the pathogen variable is no longer significant after seasonal terms are added. 
†For example, 0.60/0.40 for RSV indicates a standardized ȕ of 0.60 for RSV in the model with only pathogen variables and a ȕ of 0.40 in the same model 
after adding seasonal terms. RESEARCH
speciﬁ  c asthma diagnoses were excluded from the respira-
tory syndrome deﬁ  nitions, exacerbations of asthma might 
affect other respiratory categories in the GP or pharmacy 
syndrome. This observation illustrates that additional diag-
nostics are needed for identifying the causes of unexplained 
respiratory disease elevations. Several novel respiratory 
pathogens for which diagnostics are not yet widely avail-
able have been discovered in recent years, underlining that 
it is quite possible that “hidden” epidemics occur (34–36). 
The extra October peak and several other syndrome eleva-
tions above the 95% UCLs in our study may well reﬂ  ect 
such hidden epidemics. The fact that these occur is sup-
ported by studies showing that many individual syndrome 
cases cannot be linked to known pathogens. For example, 
Cooper et al. (37), who investigated syndromic signals by 
using patient self-sampling (at home), could only obtain di-
agnostic results for 22% of these cases.
For early warning surveillance, timeliness is crucial. 
Absenteeism data seem to have the best timeliness, but 
their lack of medical detail complicates interpretation. Un-
expectedly, the hospital data reﬂ  ect respiratory pathogen 
activity earlier than the GP data. Although in the Nether-
lands patients are encouraged to consult their GP before 
going to the hospital, elderly persons, for whom respiratory 
infections are more likely to cause severe illness, may often 
go to a hospital directly. Therefore, hospital data may prove 
to be an earlier marker for respiratory disease than GP data, 
but this possibility needs further exploration.
An important concern when using syndromic surveil-
lance is that it may generate nonspeciﬁ  c alerts, which, if 
they happen regularly, would lead to lack of conﬁ  dence in 
a syndrome-based surveillance system. Here, we see a clear 
advantage of using data from multiple registries in parallel 
so that signal detection can be made more speciﬁ  c by focus-
ing on signals that occur concurrently in >1 data source. To 
illustrate this we deﬁ  ned every exceeding of the UCLs of the 
regression models as a “signal,” i.e., a syndrome elevation 
unexplained by known pathogen activity and therefore pos-
sibly reﬂ  ecting activity of underdiagnosed or emerging in-
fectious disease. Over 2002–2003 (the period that all 6 regis-
tries were in the study), only 5 “concurrent” signals occurred 
versus 34 “single” signals over all registries. We did not 
evaluate whether the syndromes indeed detect outbreaks of 
infectious diseases earlier than clinical or laboratory patho-
gen surveillance. Such an evaluation is often performed by 
testing the ability to detect historical natural outbreaks or 
simulated outbreaks (10,38). However, historical natural 
outbreaks are rare and simulated outbreaks may be unrealis-
tic. Nevertheless, further research into the outbreak detection 
performance of these syndromes would be worthwhile.
The results of this study suggest that it might be best to 
combine syndromic data and pathogen counts in a prospec-
tive surveillance system. Such surveillance can identify 
distinct syndrome elevations that cannot be explained by 
respiratory pathogen activity as indicated by routine labo-
ratory pathogen surveillance.
Conclusion
Overall, the GP, hospital, mortality and, to a lesser 
extent, laboratory submission syndromes reﬂ  ect week-to-
week ﬂ  uctuations in the time-series of respiratory patho-
gens as detected in the laboratory. Registries monitoring 
trends of these syndromes will therefore most likely reﬂ  ect 
illness caused by emerging or underdiagnosed respiratory 
pathogens as well and therefore are suited for syndromic 
surveillance. Further research would be required to assess 
to what extent absenteeism and pharmacy data reﬂ  ect respi-
ratory illness. Investigating the actual outbreak detection 
performance of the syndromes in this study would also be 
worthwhile.
Data from the registries in this study are not yet real-
time available, although given modern information tech-
nology, this availability is clearly feasible. Our study can 
help prioritize which type of healthcare data to include in 
future syndromic real-time surveillance systems.
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